Current Report Filing (8-k)
August 16 2018 - 4:21PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 16, 2018
Pfenex Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36540
|
|
27-1356759
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
10790 Roselle Street
San Diego, CA 92121
(Address of principal executive offices, including zip code)
(858)
352-4400
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below if the Form
8-K
filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or
Rule
12b-2
of the Securities Exchange Act of 1934 (17 CFR
§240.12b-2).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On August 16, 2018, Dr. Hubert Chen notified Pfenex Inc. (the Company)
of his intention to resign as the Companys Chief Medical and Scientific Officer, effective September 2, 2018. This resignation is without Good Reason (as defined in Dr. Chens executive employment agreement with the Company). In
connection with Dr. Chens resignation, the Company entered into a transition agreement and release (the Chen Transition Agreement) with Dr. Chen. The Chen Transition Agreement provides that Dr. Chen will provide
transition services at a rate of $7,500 per month for up to 10 hours of transition services and $750 per hour for each additional hour of transition services through the earlier of (i) the approval of the new drug application (NDA)
for PF708 or (ii) September 30, 2019. The Chen Transition Agreement also provides for the payment of bonus severance at a target amount of 50% of the aggregate amount of Dr. Chens 2018 salary payments and transition period
payments paid by the Company in 2018, and is further subject to adjustment by the compensation committee of the Companys board of directors and the terms of the Chen Transition Agreement. Pursuant to the terms and conditions of the
Companys Incentive Compensation Plan and the Chen Transition Agreement, the actual bonus severance amount will be determined by (i) the achievement of corporate performance goals, (ii) Dr. Chens individual performance
goals, which are determined to have been achieved at 100%, and (iii) the actual achievement of certain special individual performance incentives. During the time Dr. Chen is providing transition services, Dr. Chen will also continue
to vest in his equity incentive awards.
The foregoing summary of the Chen Transition Agreement does not purport to be complete and is qualified in its
entirety by reference to the Chen Transition Agreement, which will be filed as an exhibit to the Companys Quarterly Report on Form
10-Q
for the quarter ended September 30, 2018.
On August 16, 2018, the Company also issued a press release announcing the foregoing management change. The full text of the press release is attached as
Exhibit 99.1 to this report and is hereby incorporated by reference herein.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
PFENEX INC.
|
|
|
|
|
Date: August 16, 2018
|
|
|
|
By:
|
|
/s/ Susan A. Knudson
|
|
|
|
|
|
|
Susan A. Knudson
|
|
|
|
|
|
|
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
-3-
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Apr 2023 to Apr 2024